AstraZeneca PLC
ISIN: GB0009895292 | Ticker: AZN | LEI: PY6ZZQWO2IZFZC3IOL08
Country: United Kingdom
We are a global, science-led, patient-focused pharmaceutical company. We are tireless in seeking to realise the potential of what science can do.
We are focused on creating genuinely innovative medicines and improving access to them. In this way, we deliver the greatest benefit to patients, healthcare systems and societies globally. We have three priorities designed to deliver our growth through innovation strategy.
Oncology
We are leading a revolution in oncology to redefine cancer care. Our ambition is to provide cures for cancer in every form.
BioPharmaceuticals
We want to change the lives of billions of people living with chronic diseases for the better.
Rare Disease
Our mission is to transform the lives of people affected by rare diseases and devastating conditions.
1999
Served areaWorldwide
Headquarters1 Francis Crick Avenue, CB2 0AA Cambridge – United Kingdom
| Line item in (usd) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 61,377,000,000.00 | 66,729,000,000.00 | 105,363,000,000.00 | 96,483,000,000.00 |
| Noncurrent Assets | N/A | 45,814,000,000.00 | 47,185,000,000.00 | 79,119,000,000.00 | 73,890,000,000.00 |
| Property Plant And Equipment | N/A | 7,688,000,000.00 | 8,251,000,000.00 | 9,183,000,000.00 | 8,507,000,000.00 |
| Goodwill | N/A | 11,668,000,000.00 | 11,845,000,000.00 | 19,997,000,000.00 | 19,820,000,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 20,833,000,000.00 | 20,947,000,000.00 | 42,387,000,000.00 | 39,307,000,000.00 |
| Investment Accounted For Using Equity Method | N/A | 58,000,000.00 | 39,000,000.00 | 69,000,000.00 | 76,000,000.00 |
| Other Noncurrent Receivables | N/A | 740,000,000.00 | 720,000,000.00 | 895,000,000.00 | 835,000,000.00 |
| Deferred Tax Assets | N/A | 2,718,000,000.00 | 3,438,000,000.00 | 4,330,000,000.00 | 3,263,000,000.00 |
| Noncurrent Derivative Financial Assets | N/A | 61,000,000.00 | 171,000,000.00 | 102,000,000.00 | 74,000,000.00 |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | N/A | 1,401,000,000.00 | 1,108,000,000.00 | 1,168,000,000.00 | 1,066,000,000.00 |
| Current Assets | N/A | 15,563,000,000.00 | 19,544,000,000.00 | 26,244,000,000.00 | 22,593,000,000.00 |
| Inventories | N/A | 3,193,000,000.00 | 4,024,000,000.00 | 8,983,000,000.00 | 4,699,000,000.00 |
| Trade And Other Current Receivables | N/A | 5,761,000,000.00 | 7,022,000,000.00 | 9,644,000,000.00 | 10,521,000,000.00 |
| Cash and cash equivalents | N/A | 5,369,000,000.00 | 7,832,000,000.00 | 6,329,000,000.00 | 6,166,000,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | 70,000,000.00 | 0.00 | 368,000,000.00 | 150,000,000.00 |
| Current Derivative Financial Assets | N/A | 36,000,000.00 | 142,000,000.00 | 83,000,000.00 | 87,000,000.00 |
| Current Investments | N/A | 849,000,000.00 | 160,000,000.00 | 69,000,000.00 | 239,000,000.00 |
| Equity | 14,044,000,000.00 | 14,596,000,000.00 | 15,638,000,000.00 | 39,287,000,000.00 | 37,058,000,000.00 |
| Issued Capital | N/A | 328,000,000.00 | 328,000,000.00 | 387,000,000.00 | 387,000,000.00 |
| Retained Earnings | N/A | 2,812,000,000.00 | 5,299,000,000.00 | 1,710,000,000.00 | -574,000,000.00 |
| Share Premium | N/A | 7,941,000,000.00 | 7,971,000,000.00 | 35,126,000,000.00 | 35,155,000,000.00 |
| Capital Redemption Reserve | N/A | 153,000,000.00 | 153,000,000.00 | 153,000,000.00 | 153,000,000.00 |
| Merger Reserve | N/A | 448,000,000.00 | 448,000,000.00 | 448,000,000.00 | 448,000,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 13,127,000,000.00 | 15,622,000,000.00 | 39,268,000,000.00 | 37,037,000,000.00 |
| Noncontrolling Interests | N/A | 1,469,000,000.00 | 16,000,000.00 | 19,000,000.00 | 21,000,000.00 |
| Liabilities | N/A | 46,781,000,000.00 | 51,091,000,000.00 | 66,076,000,000.00 | 59,425,000,000.00 |
| Noncurrent Liabilities | N/A | 28,664,000,000.00 | 30,784,000,000.00 | 43,482,000,000.00 | 33,132,000,000.00 |
| Noncurrent Provisions | N/A | 841,000,000.00 | 584,000,000.00 | 956,000,000.00 | 896,000,000.00 |
| Noncurrent Payables | N/A | 6,291,000,000.00 | 6,084,000,000.00 | 4,933,000,000.00 | 4,270,000,000.00 |
| Deferred Tax Liabilities | N/A | 2,490,000,000.00 | 2,918,000,000.00 | 6,206,000,000.00 | 2,944,000,000.00 |
| Noncurrent Recognised Liabilities Defined Benefit Plan | N/A | 2,807,000,000.00 | 3,202,000,000.00 | 2,454,000,000.00 | 1,168,000,000.00 |
| Noncurrent Derivative Financial Liabilities | N/A | 18,000,000.00 | 2,000,000.00 | 45,000,000.00 | 164,000,000.00 |
| Longterm Borrowings | N/A | 15,730,000,000.00 | 17,505,000,000.00 | 28,134,000,000.00 | 22,965,000,000.00 |
| Current Liabilities | N/A | 18,117,000,000.00 | 20,307,000,000.00 | 22,594,000,000.00 | 26,293,000,000.00 |
| Current Provisions | N/A | 723,000,000.00 | 976,000,000.00 | 768,000,000.00 | 722,000,000.00 |
| Trade And Other Current Payables | N/A | 13,987,000,000.00 | 15,785,000,000.00 | 18,938,000,000.00 | 19,040,000,000.00 |
| Current Derivative Financial Liabilities | N/A | 36,000,000.00 | 33,000,000.00 | 79,000,000.00 | 93,000,000.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 1,822,000,000.00 | 2,194,000,000.00 | 1,660,000,000.00 | 5,314,000,000.00 |
| Line item in (usd) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 24,384,000,000.00 | 26,617,000,000.00 | 37,417,000,000.00 | 44,351,000,000.00 |
| Revenue From Sale Of Goods | 23,565,000,000.00 | 25,890,000,000.00 | 36,541,000,000.00 | 42,998,000,000.00 |
| Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 3,762,000,000.00 | 3,149,000,000.00 | 6,530,000,000.00 | 5,480,000,000.00 |
| Profit Loss From Operating Activities | 2,924,000,000.00 | 5,162,000,000.00 | 1,056,000,000.00 | 3,757,000,000.00 |
| Finance Income | 172,000,000.00 | 87,000,000.00 | 43,000,000.00 | 95,000,000.00 |
| Finance Costs | 1,432,000,000.00 | 1,306,000,000.00 | 1,300,000,000.00 | 1,346,000,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | -116,000,000.00 | -27,000,000.00 | -64,000,000.00 | -5,000,000.00 |
| Profit Loss Before Tax | 1,548,000,000.00 | 3,916,000,000.00 | -265,000,000.00 | 2,501,000,000.00 |
| Income Tax Expense Continuing Operations | 321,000,000.00 | 772,000,000.00 | -380,000,000.00 | -792,000,000.00 |
| Profit (loss) | 1,227,000,000.00 | 3,144,000,000.00 | 115,000,000.00 | 3,293,000,000.00 |
| Profit Loss Attributable To Owners Of Parent | 1,335,000,000.00 | 3,196,000,000.00 | 112,000,000.00 | 3,288,000,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | -108,000,000.00 | -52,000,000.00 | 3,000,000.00 | 5,000,000.00 |
| Line item in (usd) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | 1,227,000,000.00 | 3,144,000,000.00 | 115,000,000.00 | 3,293,000,000.00 |
| Adjustments For Decrease Increase In Inventories | -316,000,000.00 | -621,000,000.00 | 1,577,000,000.00 | 3,941,000,000.00 |
| Other Adjustments For Noncash Items | 378,000,000.00 | -276,000,000.00 | 95,000,000.00 | -692,000,000.00 |
| Cash Flows From Used In Operations | 4,861,000,000.00 | 7,094,000,000.00 | 8,427,000,000.00 | 12,280,000,000.00 |
| Interest Paid Classified As Operating Activities | 774,000,000.00 | 733,000,000.00 | 721,000,000.00 | 849,000,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | 1,118,000,000.00 | 1,562,000,000.00 | 1,743,000,000.00 | 1,623,000,000.00 |
| Cash Flows From Used In Operating Activities | 2,969,000,000.00 | 4,799,000,000.00 | 5,963,000,000.00 | 9,808,000,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | 0.00 | 0.00 | 9,263,000,000.00 | 48,000,000.00 |
| Other Cash Payments To Acquire Interests In Joint Ventures Classified As Investing Activities | 74,000,000.00 | 8,000,000.00 | 92,000,000.00 | 26,000,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 37,000,000.00 | 106,000,000.00 | 13,000,000.00 | 282,000,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 979,000,000.00 | 961,000,000.00 | 1,091,000,000.00 | 1,091,000,000.00 |
| Proceeds From Sales Of Intangible Assets Classified As Investing Activities | 2,076,000,000.00 | 951,000,000.00 | 587,000,000.00 | 447,000,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 1,481,000,000.00 | 1,645,000,000.00 | 1,109,000,000.00 | 1,480,000,000.00 |
| Proceeds From Other Longterm Assets Classified As Investing Activities | 18,000,000.00 | 1,381,000,000.00 | 9,000,000.00 | 42,000,000.00 |
| Purchase Of Other Longterm Assets Classified As Investing Activities | 13,000,000.00 | 119,000,000.00 | 184,000,000.00 | 45,000,000.00 |
| Interest Received Classified As Investing Activities | 124,000,000.00 | 47,000,000.00 | 34,000,000.00 | 60,000,000.00 |
| Other Inflows Outflows Of Cash Classified As Investing Activities | 194,000,000.00 | 745,000,000.00 | 96,000,000.00 | -114,000,000.00 |
| Cash Flows From Used In Investing Activities | -657,000,000.00 | -285,000,000.00 | -11,058,000,000.00 | -2,960,000,000.00 |
| Proceeds From Issuing Shares | 3,525,000,000.00 | 30,000,000.00 | 29,000,000.00 | 29,000,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | 500,000,000.00 | 2,968,000,000.00 | 12,929,000,000.00 | 0.00 |
| Repayments Of Borrowings Classified As Financing Activities | 1,500,000,000.00 | 1,609,000,000.00 | 4,759,000,000.00 | 1,271,000,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 186,000,000.00 | 207,000,000.00 | 240,000,000.00 | 244,000,000.00 |
| Dividends Paid Classified As Financing Activities | 3,592,000,000.00 | 3,572,000,000.00 | 3,856,000,000.00 | 4,364,000,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | -516,000,000.00 | 288,000,000.00 | -276,000,000.00 | 74,000,000.00 |
| Cash Flows From Used In Financing Activities | -1,765,000,000.00 | -2,203,000,000.00 | 3,649,000,000.00 | -6,823,000,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 547,000,000.00 | 2,311,000,000.00 | -1,446,000,000.00 | 25,000,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 5,000,000.00 | 12,000,000.00 | -62,000,000.00 | -80,000,000.00 |
| Cash and cash equivalents | 5,369,000,000.00 | 7,832,000,000.00 | 6,329,000,000.00 | 6,166,000,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 22.11.23 | Michel Demare | Other | Buy | EUR 101,700.00 |
| 21.11.23 | Michel Demare | Other | Buy | EUR 101,052.24 |
| 28.04.23 | Michel Demare | Other | Buy | EUR 234,020.00 |
| 23.03.23 | Pascal Soriot | Other | Other | EUR 0.00 |
| 06.03.23 | Pascal Soriot | Other | Other | EUR 0.00 |
| 04.03.23 | Pascal Soriot | Other | Other | EUR 10,848,701.76 |
| 04.03.23 | Aradhana Sarin | Other | Other | EUR 4,918,036.29 |
| 09.02.23 | Pascal Soriot | Other | Other | EUR 0.00 |
| 23.12.22 | Pascal Soriot | Other | Other | EUR 0.00 |
| 24.03.22 | Pascal Soriot | Other | Other | EUR 0.00 |
GB0009895292
LEIPY6ZZQWO2IZFZC3IOL08
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryFTSE 100
OMX Stockholm 30
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.